Metrion Biosciences’ new cardiac safety White Paper is now available to download here.
You can contact our team to discuss our high quality ion channel services via info@metrionbiosciences.com.
Leaders in Ion Channel Biology
Welcome to Metrion Biosciences
Metrion Biosciences is a UK-based Contract Research Organization (CRO) focused on delivering a range of high quality ion channel drug discovery services. We provide highly skilled electrophysiology screening services to support client medicinal chemistry optimisation programmes, CiPA compliant cardiac safety profiling assays, neuroscience assays and translational assays. Working closely with our collaborators, we also offer an expert integrated drug discovery service.
Metrion offers flexible business models according to the scope of each programme, with both fee-for-service and collaborative options available.
Our Expertise
Metrion has assembled a team of highly expert and dedicated ion channel screening specialists to support diverse ion channel drug discovery projects and modern safety assessment research. We combine in depth target class knowledge and high quality screening assays with experienced and collaborative project managers to keep your research focused upon meeting both objectives and timelines.
Our Services
Ion Channel Screening
Metrion has developed validated screening assays against an extensive panel of ion channel cell lines using a variety of high quality ion channel screening platforms with a range of throughput capabilities.
Cardiac Safety Screening
Metrion offers screening services against a premium panel of validated Comprehensive in Vitro Proarrhythmia Assay (CiPA) compliant human cardiac ion channel screening assays, which includes hERG.
Our Facilities
Metrion is located within the Cambridge bio cluster, one of Europe’s largest bioscience research hubs. Our state of the art laboratories at Granta Park house high quality facilities for native and engineered cell line and induced pluripotent stem cell culture, a comprehensive suite of automated patch clamp platforms, multiple manual patch clamp rigs, fluorescence-based screening capability and laboratory data management and reporting systems.
Latest News
Metrion Biosciences and International Scientific Consortium publish data and new recommendations for in vitro risk assessment of the cardiac safety of new medicines
Metrion Biosciences and International Scientific Consortium publish data and new recommendations for in vitro risk assessment of the cardiac [...]
Metrion Biosciences and LifeArc extend ion channel drug discovery collaboration
Metrion Biosciences and LifeArc extend ion channel drug discovery collaboration to accelerate neuroscience-focused research Initial twelve month collaboration successfully identifies [...]
Metrion Biosciences Appoints Dr Andrew Southan as Chief Executive Officer
Metrion Biosciences Appoints Dr Andrew Southan as Chief Executive Officer Cambridge, UK, 08 April 2019: Metrion Biosciences (“Metrion”), the specialist [...]